Homepage Top Section1

Follicular lymphoma, which is said to be the second most common form of non-Hodgkins lymphoma (NHL), is an indolent lymphoma and represents around 22% of NHL cases. Claimed

In this regard, Gilead Sciences and Kite have signed a three-year research collaboration agreement with oNKo-innate on cancer immunotherapies with an objective to support the discovery and development

The deal is said to leverage TScan’s advanced platform to discover novel cancer antigens, which are expected to be targeted by TCR-based therapies. TScan chief scientific officer Gavin

Braftovi, an oral small molecule kinase inhibitor, has been developed to target BRAF V600E. The approval was based on data from the BEACON CRC trial, which is claimed

In this connection, the RNAi therapeutics company completed the rolling submission of a new drug application (NDA) for lumasiran with the regulator. Considered to be an ultra-rare, life-threatening

IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The FDA fast track designation will enable the development and accelerate the review of

The company, which is a subsidiary of Roche, will evaluate the safety and efficacy of Actemra given intravenously plus standard of care in hospitalised adults with severe COVID-19

CABENUVA is now the first once-monthly, complete long-acting regimen for the treatment of HIV-1 in adults, which has been indicated to replace the current antiretroviral (ARV) regimen in

The late-stage study assessed the safety and efficacy of abrocitinib in adult patients with the skin condition, who were also on background topical therapy. According to Pfizer, the